84 related articles for article (PubMed ID: 21851485)
1. Contemporary unconventional clinical use of co-trimoxazole.
Goldberg E; Bishara J
Clin Microbiol Infect; 2012 Jan; 18(1):8-17. PubMed ID: 21851485
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2014 Apr; 69(4):1050-6. PubMed ID: 24257317
[TBL] [Abstract][Full Text] [Related]
3. Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men.
Sabbaj J; Hoagland VL; Cook T
Scand J Infect Dis Suppl; 1986; 48():48-53. PubMed ID: 3490684
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of the combination trimethoprim plus sulfamethoxazole compared with that of other chemotherapeutic agents.
Focht J; Klietmann W; Nösner K
Arzneimittelforschung; 1988 Aug; 38(8):1085-8. PubMed ID: 3264166
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of co-trimoxazole during a high-dosage regimen.
Muhammed Ameen S; Rolain JM; Le Poullain MN; Roux V; Raoult D; Drancourt M
J Antimicrob Chemother; 2014 Mar; 69(3):757-60. PubMed ID: 24123429
[TBL] [Abstract][Full Text] [Related]
6. Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria.
Grape M; Farra A; Kronvall G; Sundström L
Clin Microbiol Infect; 2005 Mar; 11(3):185-92. PubMed ID: 15715715
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the efficacy of co-trimoxazole and cephalexin in respiratory infections.
Phadtare JM; Rangnekar RY
Pharmatherapeutica; 1988; 5(3):183-8. PubMed ID: 3258993
[TBL] [Abstract][Full Text] [Related]
8. [Co-trimoxazole resistance in methicillin-resistant staphylococci isolated from clinical material in 2001-2003].
Mikołajczyk D; Kaczmarek A; Budzytiska A; Gospodarek E
Med Dosw Mikrobiol; 2005; 57(3):235-40. PubMed ID: 16494198
[TBL] [Abstract][Full Text] [Related]
9. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.
Stegeman CA; Tervaert JW; de Jong PE; Kallenberg CG
N Engl J Med; 1996 Jul; 335(1):16-20. PubMed ID: 8637536
[TBL] [Abstract][Full Text] [Related]
10. Treatment of urinary tract infections in Hong Kong: a comparative study of norfloxacin and co-trimoxazole.
Wong WT; Chan MK; Li MK; Wong WS; Yin PD; Cheng IK
Scand J Infect Dis Suppl; 1988; 56():22-7. PubMed ID: 3074462
[TBL] [Abstract][Full Text] [Related]
11. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study.
Lolekha S; Patanachareon S; Thanangkul B; Vibulbandhitkit S
Scand J Infect Dis Suppl; 1988; 56():35-45. PubMed ID: 3074464
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
13. Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial.
Tungsanga K; Chongthaleong A; Udomsantisuk N; Petcharabutr OA; Sitprija V; Wong EC
Scand J Infect Dis Suppl; 1988; 56():28-34. PubMed ID: 3074463
[TBL] [Abstract][Full Text] [Related]
14. [Surveillance on antibiotic resistance of Stenotrophomonas maltophilia in Chengdu and Chongqing area].
Tao CM; Li XC; Lü XJ; Li P; Yu RJ; Gao YY; Chen HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):91-3. PubMed ID: 14981826
[TBL] [Abstract][Full Text] [Related]
15. Influence of cefaclor, phenethicillin, co-trimoxazole and doxycycline on colonization resistance in healthy volunteers.
Vollaard EJ; Clasener HA; van Griethuysen AJ; Janssen AJ; Sanders-Reijmers AH; Muller NF; Huige PJ
J Antimicrob Chemother; 1988 Nov; 22(5):747-58. PubMed ID: 3145269
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
17. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
Grim SA; Rapp RP; Martin CA; Evans ME
Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
[TBL] [Abstract][Full Text] [Related]
18. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection. A double-blind general practice study.
Levenstein J; Summerfield PJ; Fourie S; Brink G; Michaelides B; Murray E; Naidoo N
S Afr Med J; 1986 Oct; 70(8):455-60. PubMed ID: 3535127
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
